Lung PD-L1 AI

Lung PD-L1 AI is seamlessly integrated into HALO AP®, an AI-powered platform designed to enhance anatomic pathology workflows. This integration allows pathologists to efficiently analyze PD-L1 expression in lung pathology samples.

The platform is intended for research use only and is not suitable for clinical diagnostic purposes. It is accessible through the HALO AP® enterprise digital pathology platform, which is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. However, in the USA, it is designated for research use only and lacks FDA clearance for clinical diagnostics.

HALO AP® ensures compliance with several regulatory standards, including FDA 21 CFR Part 11, HIPAA, and GDPR, providing a secure and compliant environment for research activities.

Features and Benefits:

• Seamless deployment within HALO AP® for streamlined workflow integration.
• AI-driven analysis tailored for PD-L1 expression in lung pathology.
• Regulatory compliance with major standards like FDA 21 CFR Part 11, HIPAA, and GDPR.

For those interested in exploring Lung PD-L1 AI further, Indica Labs offers live demos and additional information upon request. The platform also provides robust technical support and software maintenance options to ensure optimal performance and user satisfaction.